Kuria Therapeutics

Kuria Therapeutics is a pharmaceutical company developing novel ophthalmic and dermatological therapies, dedicated to creating new treatments for ophthalmic and skin diseases. Kuria’s lead candidate is a topical ophthalmic formulation of SCO-116, a novel Nrf2 activator being developed under license from SCOHIA PHARMA, Inc. (https://www.scohia.com/eng/).